CN102869778B - 重组毒素蛋白的高水平表达 - Google Patents

重组毒素蛋白的高水平表达 Download PDF

Info

Publication number
CN102869778B
CN102869778B CN201180018149.7A CN201180018149A CN102869778B CN 102869778 B CN102869778 B CN 102869778B CN 201180018149 A CN201180018149 A CN 201180018149A CN 102869778 B CN102869778 B CN 102869778B
Authority
CN
China
Prior art keywords
expression
pseudomonas
protein
toxin
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180018149.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102869778A (zh
Inventor
D·M·雷奥尔阿克
L·丘
H·金
H·W·塔尔伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peliken Technology Holdings Ltd
Original Assignee
Phonex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44763483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102869778(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2010/030573 external-priority patent/WO2011123139A1/en
Application filed by Phonex Corp filed Critical Phonex Corp
Publication of CN102869778A publication Critical patent/CN102869778A/zh
Application granted granted Critical
Publication of CN102869778B publication Critical patent/CN102869778B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201180018149.7A 2010-03-30 2011-03-28 重组毒素蛋白的高水平表达 Active CN102869778B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31915210P 2010-03-30 2010-03-30
US61/319,152 2010-03-30
USPCT/US2010/030573 2010-04-09
PCT/US2010/030573 WO2011123139A1 (en) 2010-03-30 2010-04-09 High level expression of recombinant crm197
US32523510P 2010-04-16 2010-04-16
US61/325,235 2010-04-16
PCT/US2011/030227 WO2011126811A2 (en) 2010-03-30 2011-03-28 High level expression of recombinant toxin proteins

Publications (2)

Publication Number Publication Date
CN102869778A CN102869778A (zh) 2013-01-09
CN102869778B true CN102869778B (zh) 2015-05-20

Family

ID=44763483

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180018149.7A Active CN102869778B (zh) 2010-03-30 2011-03-28 重组毒素蛋白的高水平表达

Country Status (10)

Country Link
US (3) US8530171B2 (https=)
EP (1) EP2553102B1 (https=)
JP (1) JP5839411B2 (https=)
KR (1) KR20130072201A (https=)
CN (1) CN102869778B (https=)
AU (1) AU2011238711B2 (https=)
CA (1) CA2793978C (https=)
MX (1) MX343356B (https=)
NZ (1) NZ602958A (https=)
WO (1) WO2011126811A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI919458B (zh) 2023-09-27 2026-03-21 藥華醫藥股份有限公司 增加藥物產量之機構及改良方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527797B1 (en) 2000-09-01 2009-05-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae 0139 conjugate vaccines
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US10722569B2 (en) * 2012-07-05 2020-07-28 Children's Medical Center Corporation Bacterial biofilm matrix as a platform for protein delivery
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN104140972B (zh) * 2013-05-07 2018-01-23 上海惠盾生物技术有限公司 白喉毒素突变体crm197的制备方法
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
DK3099800T3 (da) 2014-01-31 2021-01-11 Fina Biosolutions Llc Ekspression og oprensning af crm197 og beslægtede proteiner
US12104161B2 (en) 2014-01-31 2024-10-01 Fina Biosolutions Llc Production of soluble recombinant proteins without N-terminal methionine in E-coli
US11060123B2 (en) 2014-01-31 2021-07-13 Fina Biosolutions, Llc Production of soluble recombinant protein without n-terminal methionine
US10597664B2 (en) * 2014-01-31 2020-03-24 Fina Biosolutions, Llc Expression and purification of CRM proteins and related proteins, and protein domains
CA2968491C (en) 2014-11-20 2023-09-26 Biological E Limited Codon optimized polynucleotide for high level expression of crm197
US11371011B2 (en) 2016-04-06 2022-06-28 Plant Health Care, Inc. Beneficial microbes for delivery of effector peptides or proteins and use thereof
WO2017219004A2 (en) 2016-06-17 2017-12-21 Children's Medical Center Corporation Biofilm matrix-boosted vaccine
RU2636346C1 (ru) * 2016-07-01 2017-11-22 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Способ получения рекомбинантного экзопротеина А Pseudomonas aeruginosa
KR101908590B1 (ko) 2017-02-01 2018-10-16 (주)포바이오코리아 Crm197의 용해성 단백질 발현 및 정제 방법
EP3444269A1 (en) 2017-08-17 2019-02-20 National Research Council of Canada Systems and methods for the production of diphtheria toxin polypeptides
CA3077393A1 (en) 2017-10-27 2019-05-02 Pfenex Inc. Bacterial leader sequences for periplasmic protein expression
EP3701036A4 (en) * 2017-10-27 2021-09-01 Pfenex Inc. PROCESS FOR PRODUCING ASPARAGINASE OF E. COLI
JP7784804B2 (ja) * 2017-10-27 2025-12-12 フェネックス インク． 組み換えｅｒｗｉｎｉａアスパラギナーゼの製造のための方法
KR102905809B1 (ko) * 2018-01-19 2025-12-30 오비아이 파머 인코퍼레이티드 Crm197 단백질 발현
US10829731B2 (en) * 2018-01-25 2020-11-10 Alliance For Sustainable Energy, Llc Biocatalysts for conversion of thermochemical waste streams
KR102475419B1 (ko) * 2018-07-16 2022-12-07 주식회사 유바이오로직스 Crm197을 고농도로 발현하는 코리네박테리움 균주
EP3632465A1 (en) * 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
NL2023863B1 (en) * 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
CN114514320B (zh) * 2019-10-14 2025-04-01 先正达农作物保护股份公司 杀昆虫蛋白
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
BE1029145B1 (fr) * 2021-02-26 2022-09-27 Curavac Europe Methode de production d'une forme periplasmique de la proteine crm197
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
CN113201473B (zh) * 2021-04-22 2022-06-07 广东省科学院微生物研究所(广东省微生物分析检测中心) 香茅醇在制备促进铜绿假单胞菌毒力基因toxA表达的制剂中的应用
EP4689147A2 (en) 2023-04-05 2026-02-11 Primrose Bio, Inc. Methods and compositions for nucleic acid synthesis
CN119662671B (zh) * 2024-11-26 2025-11-25 吉林大学 一种来源于谷氨酸棒杆菌耐热元件及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031655A (zh) * 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
CN101641441A (zh) * 2007-01-31 2010-02-03 陶氏环球技术公司 用于提高表达的细菌前导序列

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4830962A (en) * 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
CA1340373C (en) 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
KR0168039B1 (ko) 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
WO1990009444A1 (en) * 1989-02-10 1990-08-23 Genesit Oy A method for producing pertussis toxin subunits
US7232671B2 (en) 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
US5834246A (en) 1989-09-18 1998-11-10 Vitec Aktiebolag Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides
DE69002817T2 (de) * 1989-11-28 1993-12-09 Wellcome Found Vakzine.
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
DE69434000T3 (de) 1993-10-05 2008-11-06 UCB Pharma Ltd., Slough Impfstoffzusammensetzungen
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
US5932714A (en) 1995-02-23 1999-08-03 Connaught Laboratories Limited Expression of gene products from genetically manipulated strains of Bordetella
NZ312502A (en) 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
WO2002038739A1 (en) 2000-11-09 2002-05-16 Univ Queensland Bacterial expression systems
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20060246036A1 (en) 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1638601B1 (en) 2003-06-23 2008-11-19 Baxter International Inc. Carrier proteins for vaccines
KR20060127857A (ko) 2003-10-29 2006-12-13 알투스 파마슈티컬스 인코포레이티드 혈장 콜레시스토키닌(ｃｃｋ) 농도 조절 및 통증 치료를위한 비-췌장 프로테아제
WO2005052151A1 (en) 2003-11-19 2005-06-09 Dow Global Technologies Inc. Improved protein expression systems
CA2546157C (en) 2003-11-21 2014-07-22 Dow Global Technolgies Inc. Improved expression systems with sec-system secretion
US20110097359A1 (en) 2003-12-12 2011-04-28 Tim Lee Production of diphtheria toxin
EP1709170B1 (en) * 2004-01-16 2018-02-21 Pfenex Inc. Expression of mammalian proteins in pseudomonas fluorescens
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP2021489A2 (en) 2006-05-30 2009-02-11 Dow Global Technologies Inc. Codon optimization method
WO2007146139A2 (en) 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) * 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2010008764A1 (en) * 2008-06-23 2010-01-21 Dow Global Technologies Inc. Pseudomonas fluorescens strains for production of extracellular recombinant protein
GB0917647D0 (en) * 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031655A (zh) * 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
CN101641441A (zh) * 2007-01-31 2010-02-03 陶氏环球技术公司 用于提高表达的细菌前导序列

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium;Guilin Yang等;《BMC Microbiology》;20081106;第8卷(第192期);1-13 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI919458B (zh) 2023-09-27 2026-03-21 藥華醫藥股份有限公司 增加藥物產量之機構及改良方法

Also Published As

Publication number Publication date
KR20130072201A (ko) 2013-07-01
WO2011126811A3 (en) 2012-03-08
JP5839411B2 (ja) 2016-01-06
AU2011238711B2 (en) 2015-06-18
US20150361405A1 (en) 2015-12-17
MX2012011103A (es) 2015-05-15
US8530171B2 (en) 2013-09-10
AU2011238711A1 (en) 2012-11-08
BR112012024898A2 (pt) 2015-10-06
EP2553102B1 (en) 2015-12-09
EP2553102A4 (en) 2013-10-23
US20140051093A1 (en) 2014-02-20
EP2553102A2 (en) 2013-02-06
CA2793978C (en) 2021-08-03
US20110287443A1 (en) 2011-11-24
CN102869778A (zh) 2013-01-09
WO2011126811A2 (en) 2011-10-13
MX343356B (es) 2016-11-03
JP2013529064A (ja) 2013-07-18
US8906636B2 (en) 2014-12-09
CA2793978A1 (en) 2011-10-13
NZ602958A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
CN102869778B (zh) 重组毒素蛋白的高水平表达
CN102858981B (zh) 重组crm197的高水平表达
Calvio et al. Swarming differentiation and swimming motility in Bacillus subtilis are controlled by swrA, a newly identified dicistronic operon
Overbye et al. Genes required for extracellular secretion of enterotoxin are clustered in Vibrio cholerae
JP7784804B2 (ja) 組み換えｅｒｗｉｎｉａアスパラギナーゼの製造のための方法
Dupuy et al. Regulation of toxin and bacteriocin gene expression in Clostridium by interchangeable RNA polymerase sigma factors
US11046964B2 (en) Method for production of recombinant E. coli asparaginase
McClain et al. Lipoprotein processing and sorting in Helicobacter pylori
Dahl et al. Identification of a phosphotransferase system of Escherichia coli required for growth on N-acetylmuramic acid
Son et al. Lipase and protease double-deletion mutant of Pseudomonas fluorescens suitable for extracellular protein production
van Wely et al. Functional identification of the product of the Bacillus subtilis yvaL gene as a SecG homologue
Guo et al. Identification and characterization of genes required for early Myxococcus xanthus developmental gene expression
Yang et al. Differential translocation of protein precursors across SecY-deficient membranes of Escherichia coli: SecY is not obligatorily required for translocation of certain secretory proteins in vitro
BR112012024898B1 (pt) Método para produção de uma proteína de toxina recombinante em uma célula hospedeira de pseudomonad
US6506579B1 (en) Increasing production of proteins in gram-positive microorganisms using SecG
Weeramantri Conjugative transfer and instability of beta-toxin plasmids of C. perfringens type C
Ramagoma Development of a lipase gene expression and secretion system for the protein over-production in Bacillus licheniformis
Leite Construction of an efficient secretion system for recombinant proteins in Bacillus subtilis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240329

Address after: California, USA

Patentee after: Peliken Technology Holdings Ltd.

Country or region after: U.S.A.

Address before: California, USA

Patentee before: PHONEX Corp.

Country or region before: U.S.A.